FGFR2 in-frame deletion occurred in patients with ICC at the highest frequency (0.62%, 7/1122) compared with others, followed by lung squamous carcinoma (0.53%, 5/945) and endometrioid carcinoma (0.53%, 1/188). This evidence concerns the gene FGFR2 and endometrioid adenocarcinoma.